BELMONT, Calif., June 24, 2025 /PRNewswire/ -- Supercede Therapeutics, Inc., a startup biotech company focused on small molecule drug development, today announced preclinical efficacy data from its ...
LONDON, August 26, 2025--(BUSINESS WIRE)--CyberCube, the market leader in cyber risk analytics, and Supercede, the global reinsurance technology platform, have announced a strategic partnership that ...
CyberCube, the firm focused on cyber risk analytics, and Supercede, the global reinsurance technology platform, have announced a partnership that will make cyber reinsurance placements faster, cleaner ...
Supercede Therapeutics Inc. has released preclinical efficacy data on its small-molecule inhibitor of the Activin receptor type II (ACTRII) to treat obesity. Supercede’s lead candidate, SPCD-4-79, is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results